2019
DOI: 10.1358/dof.2019.44.10.3058864
|View full text |Cite
|
Sign up to set email alerts
|

Brolucizumab. Anti-VEGF-A monoclonal antibody, Treatment of age-related macular degeneration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…A study has shown that an increase in VEGFA is sufficient to cause both forms of AMD pathologies [ 25 ]. Brolucizumab that binds to the major isoforms of VEGFA has been administered as an effective treatment for neovascular AMD [ 26 ]. There are distinct anti-VEGF molecules available for AMD treatment based on their structure and function; however, the risk of intravitreal injections and economic cost burden still exists [ 27 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A study has shown that an increase in VEGFA is sufficient to cause both forms of AMD pathologies [ 25 ]. Brolucizumab that binds to the major isoforms of VEGFA has been administered as an effective treatment for neovascular AMD [ 26 ]. There are distinct anti-VEGF molecules available for AMD treatment based on their structure and function; however, the risk of intravitreal injections and economic cost burden still exists [ 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…A study has shown that an increase in VEGFA is sufficient to cause both forms of AMD pathologies [25]. Brolucizumab that binds to the major isoforms of VEGFA has been administered as an effective treatment for neovascular AMD [26].…”
Section: Discussionmentioning
confidence: 99%